Unknown

Dataset Information

0

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.


ABSTRACT: We evaluated a DNA plasmid-vectored vaccine and a recombinant modified vaccinia virus Ankara vaccine (MVA-mBN32), each encoding cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) in a randomized, double-blinded, placebo-controlled trial in 36 HIV-1-uninfected adults using a heterologous prime-boost schedule. HIV-1-specific cellular immune responses, measured as interleukin-2 and/or gamma interferon production, were induced in 1 (4%) of 28 subjects after the first MVA-mBN32 immunization and in 3 (12%) of 25 subjects after the second MVA-mBN32 immunization. Among these responders, polyfunctional T-cell responses, including the production of tumor necrosis factor alpha and perforin, were detected. Vaccinia virus-specific antibodies were induced to the MVA vector in 27 (93%) of 29 and 26 (93%) of 28 subjects after the first and second immunizations with MVA-mBN32. These peptide-based vaccines were safe but were ineffective at inducing HIV-1-specific immune responses and induced much weaker responses than MVA vaccines expressing the entire open reading frames of HIV-1 proteins.

SUBMITTER: Gorse GJ 

PROVIDER: S-EPMC3346329 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.

Gorse Geoffrey J GJ   Newman Mark J MJ   deCamp Allan A   Hay Christine Mhorag CM   De Rosa Stephen C SC   Noonan Elizabeth E   Livingston Brian D BD   Fuchs Jonathan D JD   Kalams Spyros A SA   Cassis-Ghavami Farah L FL  

Clinical and vaccine immunology : CVI 20120307 5


We evaluated a DNA plasmid-vectored vaccine and a recombinant modified vaccinia virus Ankara vaccine (MVA-mBN32), each encoding cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) in a randomized, double-blinded, placebo-controlled trial in 36 HIV-1-uninfected adults using a heterologous prime-boost schedule. HIV-1-specific cellular immune responses, measured as interleukin-2 and/or gamma interferon production, were induced in 1 (4%) of 28 subjects after the  ...[more]

Similar Datasets

| S-EPMC6913121 | biostudies-literature
| S-EPMC5564012 | biostudies-literature
| S-EPMC3938943 | biostudies-literature
| S-EPMC5008759 | biostudies-literature
| S-EPMC2863849 | biostudies-literature
| S-EPMC4349667 | biostudies-literature
| S-EPMC2838212 | biostudies-literature
| S-EPMC3592345 | biostudies-literature
| S-EPMC7506042 | biostudies-literature
| S-EPMC7115540 | biostudies-literature